Interstitial cystitis and bladder pain syndrome (IC/BPS) vary in clinical manifestation, according to a study published online Oct. 18 in the International Journal of Urology.

Objectives Biological therapy represents important advances in alleviating rheumatoid arthritis (RA), but the effect on interstitial lung disease (ILD) has been controversial. The objective of this ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Spain Background Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are the recommended drugs [1-2]. JAK inhibitors (JAKi) ...

DEAR DR. ROACH: I am a 63-year-old male in good health. A few weeks back, I could not urinate while standing. The only way I ...

Welcome to the Lancet Global Burden of Disease (GBD) Resource Centre, bringing together the most comprehensive data and analysis of worldwide trends in global health, published across the Lancet ...

[103] As it is mainly a diagnosis of exclusion, urinalyses, urodynamics, cystoscopy with bladder distension and bladder biopsy are commonly performed investigations, although their relevance and ...

[4] Up to 55% of PMR patients have relapsing disease and require long-term steroid treatment. In one descriptive study, the initial dose was linked to treatment duration and cumulative dosage ...